Aktuellt
SENASTE
Redeye leaves a comment on the Q4 report published by Alzinova earlier today. Overall, the report did not include any major surprises. Following the positive results from the phase Ib study with ALZ-101, the main focus ahead will be to achieve a licensing deal. For now, we reiterate our fair value range (SEK2 – SEK24) with a base case valuation of SEK12.
LÄS MER
